EPHA welcomes the Commission’s publication of comprehensive consultation guidelines. Smart regulation should mean fair and citizen-centred policy making that brings tangible benefits to the citizens of Europe and improves their quality of life. This involves greater use of evidence-based impact assessment and improving the consultation process.
The aim of the guidelines should be to ensure transparency and representativeness. Publishing consultation responses, as well as explanations (...)
October 22th 2014, Brussels – The NGO signatories of this statement wholeheartedly welcome the announcement of the reversal of the decision by President-elect Jean-Claude Juncker to move the competence for pharmaceutical and medical devices to the enterprise directorate (1).
Following negotiations within the European Parliament and concerns expressed by a number of member states, President-elect Juncker stated today that the "responsibility for medicines and pharmaceutical products (...)
Health is a fundamental universal right and access to medicines is part of it. The EU and its Member States are committed to universal and equitable access to healthcare. Nevertheless, millions of European patients suffer from the lack of affordability of many life-saving medicines across Europe.
Download the event’s invitation
* See the event’s poster
An event under the auspices of MEPs Nessa CHILDERS (S&D, IE), Beatriz BECERRA BASTERRECHEA (ALDE, ES), Kostas (...)
14 October 2014, Brussels - . The European Commission’s High Level Group on Administrative Burdens (1), chaired by Dr Edmund Stoiber, has drawn severe criticism from 4 of a total of 15 Members (2) for its final report (3) pushing an outdated, deregulatory agenda.
Almost one third of ‘Stoiber group’ members oppose biased final report
The views of members representing trade unions, environmental groups, consumer organisations and health groups are presented in a (...)
October 10th 2014, Brussels – According to statements by both the S&D (1) and Green Groups (2) yesterday, it seems likely that President-elect Jean-Claude Juncker is intending to soften his decision to move pharmaceutical policy from the health portfolio to enterprise. EPHA welcomes this news as a step in the right direction and a possible cause for celebration for the European Parliament (3) and the public health community (4).
“I would like to applaud President-elect (...)
After the Hearing of the Hungarian Commissioner Candidate Tibor Navracsics, the European Parliament Committee on Culture and Education rejected him, for the nominated portfolio - Education, Culture, Youth and Citizenship - while confirming him, as a Commissioner. This move is a result of controversial policies in Hungary with regard to civil society, media freedom and respect of Fundamental Rights and the rule of law. The inevitable reshuffle of the Commission provides for a next round of (...)
“Placing pharma policy in DG Enterprise was justified. It has traditionally been in DG Enterprise, but was moved to DG Sanco and has once again been instated as an Enterprise competence” said during her hearing Commissioner-designate Elzbieta Bienkowska.
By Dorota Sienkiewicz,Health Equity and Policy Coherence Coordinator, and Martyna Giedrojć, EPHA Policy Officer for Health Systems
The pharmaceutical industry is the biggest sector in the world. In terms of production, (...)
Brussels, 2 October 2014 - We are writing to support Member States who have already expressed their concerns on the decision of European Commission President Elect Jean-Claude Juncker to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of Internal Market and Industry within the new Commission. We would like to ask for your full support to have that decision reversed.
Dear Head of States, Dear Prime (...)
1 October 2014, Brussels - By European Parliament standards, Commissioner-designate Vytenis Andriukaitis’ performance could be judged to be “satisfactory”. He showed his commitment to protect European citizens’ health and well-being, and improve underlying determinants of health and physical environment. Now we will really have to see how he intends to turn words into concrete action. He was very outspoken on the issues of prevention, promotion and protection of (...)
September 29 2014, Brussels - When questioning the EU Commissioners-designate this week, Members of the European Parliament (MEPs) should reject the decision by Jean-Claude Juncker, the European Commission President-elect, to move pharmaceutical policy from the health to the enterprise portfolio (1). The main driver of EU policies concerning pharmaceuticals and health technologies should be promoting and protecting health and patient safety, not simply boosting the competitiveness of the (...)